31st March 2016

SILODOSIN 4mg, 8mg capsules

Direct Healthcare Professional Communication on the association of silodosin “Urorec” with Intraoperative Floppy Iris Syndrome (IFIS)

Summary

This communication is to inform you that silodosin is a new highly selective α1A-adrenoceptor antagonist that has received a regulatory approval by the EMEA for the treatment of the signs and symptoms of benign prostatic hyperplasia. Silodosin will be marketed in Malta under the trade name Urorec 8mg/4mg as from February 2016. Silodosin belongs to the same pharmacological class as tamsulosin, alfuzosin, doxazosin, and terazosin.

A recently diagnosed surgical condition named “Intraoperative Floppy Iris Syndrome” (IFIS) has been observed during cataract surgery in some patients currently or previously treated with tamsulosin, and in rare cases under treatment with other α1-adrenoceptor antagonists, such as alfuzosin and doxazosin.

One case of IFIS has been observed during the silodosin clinical development program. A total of twenty-nine cases have been reported during the post-marketing experience since May 2006, indicating that silodosin is also associated with IFIS.

During pre-operative assessment, eye surgeons and ophthalmic teams should consider whether patients scheduled for cataract surgery are being or have been treated with silodosin in order to ensure that appropriate measures are in place to manage IFIS during surgery.

The content of this letter has been agreed with the European Medicines Agency and the Malta Medicines Authority.

Further information on IFIS

IFIS is a variant of small pupil syndrome that may lead to increased surgical procedural complications during cataract surgery. It is characterised by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite pre-operative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification or side incisions.

Further information on recommendation to healthcare professionals

- Cataract surgeons should ask their patients about past or current use of α1-adrenoceptor antagonists before surgery
- Initiation of therapy with silodosin is not recommended in patients for whom cataract surgery is scheduled.
- Discontinuing treatment with α1-adrenoceptor antagonists 2 weeks prior to cataract surgery has been recommended, but the benefit and duration of stopping therapy prior to cataract surgery has not yet been established.

Call for reporting

Please remember that any suspected adverse reactions following the use of Urorec or medication errors should be reported.

Adverse Drug Reaction and medication errors should be reported to the Medicines Authority. Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and sent to ADR reporting/Post-Licensing Directorate/Medicines Authority, 203, Level 3, Rue D'Argens, Gzira GZR 1368, Malta, or sent by email to: Postlicensing.medicinesauthority@gov.mt or Recordati Ireland Ltd.

Communication information

Should you require further information, please contact the medical representatives of our company:
Focused Pharma Ltd. 37 Geronimo Abos Street Iklin IK1102 Malta Tel: +356 79426930/ +35679220060
References


FLOW CHART

All patients scheduled to undergo cataract surgery

Ask about previous or current treatment with α-1 adrenoceptor antagonists (including silodosin)

Previous/ongoing treatment

No previous treatment

- Record start and stop date (if applicable) of α-1 adrenoceptor antagonists therapy (including silodosin).
- Please consider that discontinuing treatment with α-1 adrenoceptor antagonists 2 weeks prior to cataract surgery has been recommended, but that the benefit and duration of stopping therapy prior to cataract surgery has not yet been established.
- Inform the Family Doctor that an intervention of cataract surgery is scheduled and that initiation of α-1 adrenoceptor antagonists treatment (including silodosin) is not recommended.
- Ensure that appropriate measures are in place to manage IFIS during surgery.

Inform the Family Doctor of the patient that an intervention of cataract surgery is scheduled and that initiation of α-1 adrenoceptor antagonists treatment (including silodosin) is not recommended.